SAN DIEGO, Aug. 31, 2016 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name "INGREZZA(TM)" for the Company's once-daily ... 4 Traders, 4 hours ago
Neurocrine Announces FDA Conditional Acceptance of Proprietary Name INGREZZA(TM) for VMAT2 Inhibitor Valbenazine - Freshnews.com, 27 minutes ago
1 images for "unique pharmaceutical laboratories"
Dengue Virus Proteins 12-month shelf life Aalto Bio Reagents, Dublin, Ireland, offers a line of Dengue virus proteins from serotypes 14 for diagnostic test manufacturers, vaccine developers, and researchers. The upsurge in Zika virus serology and ...Clinical Lab Products, 3 hours ago
on your WebpageAdd Widget >Get your members hooked!